Demyelination in multiple sclerosis
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
This review, focused on demyelination in multiple sclerosis, is divided in two parts. The first part addresses the many and not exclusive mechanisms leading to demyelination in the central nervous system. Although the hypothesis that a primary oligodendrocyte or myelin injury induces a secondary immune response in the central nervous system is still a matter of debate, most recent advances underline the influence of a primary immune response against myelin antigen(s), with a diversity of potential targets. Whereas multiple sclerosis was long considered as a T cell-mediated disease, the role of B lymphocytes is now increasingly recognized, and the influence of antibodies on tissue damage actively investigated. The second part of the review describes the axonal consequences of demyelination. Segmental demyelination results in conduction block or slowing of conduction through adaptative responses, notably related to modifications in the distribution of voltage gated sodium channels along the denuded axon. If demyelination persists, these changes, as well as the loss of trophic and metabolic support, will lead to irreversible axonal damage and loss. In this respect, favouring early myelin repair, during a window of time when axonal damage is still reversible, might pave the way for neuroprotection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071 · cited 1×
“Moreover, a clinical study in MS patients has reported worsening of the disease in patients receiving IFN-g (Panitch et al., 1987), although a link with increased demyelination has not been demonstrated.”
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., Friese, M., Schröder, R., Deckert, M., Schmidt, S., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.3.393 · Cited by 951
Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis
Greter, M., Heppner, F. L., Lemos, M. P., Odermatt, B. M., Goebels, N., Laufer, T., Noelle, R. J., & Becher, B. (2005) · Nature Medicine · doi:10.1038/nm1197 · Cited by 862
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis
McMahon, E. J., Bailey, S. L., Castenada, C. V., Waldner, H., & Miller, S. D. (2005) · Nature Medicine · doi:10.1038/nm1202 · Cited by 694 · cited 6×
“Epitope spreading is characterized by a widening of the immune response from a single antigenic epitope to different epitopes, either on the same molecule (e.g., the intramolecular epitope spreading observed for PLP) or on other molecules.”
InfluentialImmunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions
Hauser, S. L., Bhan, A. K., Gilles, F., Kemp, M., Kerr, C., & Weiner, H. L. (1986) · Annals of Neurology · doi:10.1002/ana.410190610 · Cited by 399
Einheber, S., Zanazzi, G., Ching, W., Scherer, S., Milner, T. A., Peles, E., & Salzer, J. L. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.6.1495 · Cited by 369
Kotter, M. R., Zhao, C., van Rooijen, N., & Franklin, R. J. M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.019 · Cited by 331
Charles, P., Hernandez, M. P., Stankoff, B., Aigrot, M. S., Colin, C., Rougon, G., Zalc, B., & Lubetzki, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100076197 · Cited by 306 · cited 1×
“During development PSA-NCAMhas been shown, both in vitro and in vivo, to regulate myelination negatively, and removing it from the axonal surface is necessary to initiate the process of myelination (Charles et al., 2000).”
Self-citation
Cited by
Jakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 597
The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration
Azam, S., Haque, M. E., Balakrishnan, R., Kim, I.-S., & Choi, D.-K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683459 · Cited by 255
Matthews, P. M., & Datta, G. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1032240 · Cited by 28
“Enhancement of oligodendroglial regeneration and remyelination are being explored as neuroprotective strategies [2].”
BackgroundRemyelinating effect driven by transferrin‐loaded extracellular vesicles
Mattera, V., Occhiuzzi, F., Correale, J., & Pasquini, J. M. (2024) · Glia · doi:10.1002/glia.24478 · Cited by 21
“…prove beneficial, as the increase in microglial phagocytic capacity triggered by Tf in vitro (Carden et al., 2019) Demyelination has significant consequences for axons, both in terms of disturbed impulse conduction and changes in axonal nutrition (Gibson et al., 2014; Lubetzki & Stankoff, 2014).”
BackgroundMa, Q., Matsunaga, A., Ho, B., Oksenberg, J. R., & Didonna, A. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01964-5 · Cited by 14
Metadata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Demyelination in multiple sclerosis. https://app.cochat.ai/papers/10.1016/b978-0-444-52001-2.00004-2
- The paper
- Demyelination in multiple sclerosis. (2014). Handbook of Clinical Neurology. https://doi.org/10.1016/b978-0-444-52001-2.00004-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.